An observational study in Cardiovascular Diseases (CVD), Type 2 Diabetes and Chronic Respiratory Diseases, sponsored by Asfendiyarov Kazakh National Medical University. Recruiting at 1 site in Kazakhstan. Open to participants aged 18 Years to 69 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-11.
Sponsored by Asfendiyarov Kazakh National Medical University · Observational
This study aims to enhance personalized and preventive care for non-communicable diseases (NCDs) in Kazakhstan by examining epigenetic factors, predicting biological age and reproductive function using machine learning, and developing health improvement recommendations.
5,368 studies on the registry are indexed under Cardiovascular Diseases; 939 are open to participants now.
This study's planned enrollment of 6,720 is above the median of 506 across 1,572 observational studies indexed under Cardiovascular Diseases.
Browse Cardiovascular Diseases studies →Asfendiyarov Kazakh National Medical University is the lead sponsor of 19 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The study population consists of 6,720 adult volunteers aged 18 to 69 years, residing across 17 regions of Kazakhstan. Participants are stratified by age and gender to ensure balanced representation within the following age groups:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study follows a multistage cluster sampling design with age and gender stratification. A total of 1 cohorts have been identified, further divided into 4 age subgroups: 1. 18-29 years 2. 30-44 years 3. 45-59 years 4. 60-69 years Each age group is designed to have an equal distribution of men and women, ensuring gender balance across all subgroups.
Other: Genetic: DNA analysis
Investigation of telomere length (TL) and DNA methylation level analysis
Accuracy of Machine Learning Model for Predicting Biological Age
Evaluation of the model's performance (based on telomere length and DNA methylation) using Mean Absolute Error (MAE), Mean Squared Error (MSE), and R².
Time frame: Within 10 months from start of data collection
Accuracy of Reproductive Function Prediction Model
Development and validation of machine learning model to predict reproductive function using biomarkers. Model performance evaluated via MAE, MSE, and R².
Time frame: Within 10 months from start of data collection
Plan to share: Undecided
No publications or documents are linked to this record.
Started Mar 2025 (actual). Primary completion is estimated for Jan 2026, 9 months after the start.
Of 580 non-industry observational studies under Cardiovascular Diseases, half reached primary completion within 70 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 196. This study's planned 9 months is below that.
Counting every sponsor, half of 664 studies reached it within 61 months; a quarter within 24 and three quarters within 192.
Cardiovascular Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Asfendiyarov Kazakh National Medical University